Skip to main content
. 2022 Jan 6;8(3):345–353. doi: 10.1001/jamaoncol.2021.6628

Table 1. Baseline Characteristics of the Study Patientsa.

Characteristic 5-d Regimen (n = 293) 1-d Regimen (n = 311) Total (n = 604)
Patient demographic characteristics and tumor details
Age, mean (SD), y 42.6 (21.7) 39.9 (22.0) 41.2 (21.9)
Sex
Male 178 (60.8) 183 (58.8) 361 (59.8)
Female 115 (39.2) 128 (41.2) 243 (40.2)
Race and ethnicity
Asian 54 (18.4) 60 (19.4) 114 (18.9)
Black 21 (7.2) 22 (7.1) 43 (7.1)
Hispanic 14 (4.8) 20 (6.5) 34 (5.6)
Indigenous 4 (1.4) 11 (3.6) 15 (2.5)
White 194 (66.2) 190 (61.5) 384 (63.8)
Otherb 6 (2.0) 6 (1.9) 12 (2.0)
Unknown 0 2 2
Systemic metastases
No 244 (83.3) 255 (82.0) 499 (82.6)
Yes 49 (16.7) 56 (18.0) 105 (17.4)
Other cancer treatment modalities
No 157 (53.6) 138 (44.4) 295 (48.8)
Yes 136 (46.4) 173 (55.6) 309 (51.2)
Preoperative chemotherapy 129 (44.0) 161 (51.8) 290 (48.0)
Preoperative radiation 10 (3.4) 12 (3.9) 22 (3.6)
Other 7 (2.4) 7 (2.3) 14 (2.3)
Location of tumor
Tibia 53 (18.1) 55 (17.7) 108 (17.9)
Femur 240 (81.9) 256 (82.3) 496 (82.1)
Type of tumor
Bone tumor 237 (80.9) 249 (80.1) 486 (80.5)
Soft tissue sarcoma 28 (9.6) 34 (10.9) 62 (10.3)
Oligometastatic bone disease 28 (9.6) 28 (9.0) 56 (9.3)
Neutropenia at time of surgeryc
No. of patients 275 286 561
No 231 (84.0) 234 (81.8) 465 (82.9)
Yes 44 (16.0) 52 (18.2) 96 (17.1)
Surgical and perioperative management details
Length of procedure, median (Q1-Q3), min 270 (206-377) 270 (200-377) 270 (205-377)
Antibiotic or silver-coated prosthesis
No. of patients 292 311 603
No 276 (94.5) 295 (94.9) 571 (94.7)
Yes 16 (5.5) 16 (5.1) 32 (5.3)
Antibiotic 6 (2.1) 6 (1.9) 12 (2.0)
Silver-coated prosthesis 10 (3.4) 10 (3.2) 20 (3.3)
Suction drain used
No. of patients 293 310 603
No 63 (21.5) 74 (23.9) 137 (22.7)
Yes 230 (78.5) 236 (76.1) 466 (77.3)

Abbreviation: Q1-Q3, quartile 1 to quartile 3.

a

Data are presented as number (percentage) of patients unless otherwise indicated.

b

Other ethnicity includes Middle Eastern (n = 3), mixed race (n = 5), North African (n = 2), Polynesian (n = 1), and Turkish (n = 1).

c

Absolute neutrophil count of 1500/μL or less (to convert to ×109/L, multiply by 0.001).